Clinical phenomenology in children and adolescents with bipolar disorder

Sena Aksoy1, Gul Karacetin2, Nurdan Unaldi2, Caner Mutlu3

1Kastamonu Training and Research Hospital, Department of Child and Adolescent Psychiatry, Kastamonu, Turkiye
2Bakirkoy Prof. Mazhar Osman Training and Research Hospital for Psychiatry, Neurology, and Neurosurgery, Department of Child and Adolescent Psychiatry, Istanbul, Turkiye
3Basaksehir Cam and Sakura City Hospital, Department of Child and Adolescent Psychiatry, Istanbul, Turkiye

ABSTRACT

**Objective:** The aim of our study was to evaluate the clinical phenomenology, prognosis, comorbidity, and the effect of resilience on clinical course in hospitalized children and adolescents with bipolar disorder (BD) by comparing them with and without psychotic features.

**Method:** The study group included 60 cases with BD in the inpatient unit of the Child and Adolescent Psychiatry Clinic of Bakirkoy Prof. Mazhar Osman Training and Research Hospital for Psychiatry, Neurology and Neurosurgery. Psychiatric assessment and comorbid disorders were established using the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version. We also administered the Young Mania Rating Scale (YMRS) for manic symptoms, Positive and Negative Syndrome Scale (PANSS) for psychotic symptoms, Child and Youth Resilience Measure, and Children Global Assessment Scale to the patients. The patients were evaluated during the remission period.

**Results:** Psychotic symptoms were found in 76.7% of the cases in our study. They were significantly higher in male cases. The most common symptom found was a decreased need for sleep. The scores of YMRS and PANSS were significantly higher in psychotic cases. The comorbidity of Attention Deficit Hyperactivity Disorder was found to be significantly higher in nonpsychotic cases. No difference was found in both groups in terms of resilience.

**Conclusion:** Poor judgment and persecutory delusions were predictors of poor clinical course in children and adolescents with BD. Evaluating relevant predictors in larger study samples will provide more significant results in predicting clinical course in patients with BD.

**Keywords:** Adolescents, bipolar disorder, children, clinical phenomenology

INTRODUCTION

Bipolar disorder (BD) is a lifelong psychiatric disorder that significantly affects the quality of life from 1% to 2% (1). In retrospective studies of adult cases, approximately 30%–60% of the cases have been shown to have an onset age before the age of 20 years, and in one-fourth of these, the first mood episode is before the age of 13 years (2).

Adolescents with BD experience more severe symptoms and worse prognosis compared with adults (3). It was reported that the time spent with the disease was longer in cases with BD symptoms before the age of 12 years (4,5). BD is estimated to be the leading cause of disability in individuals aged 10–24 years (6). Studies showed that early-onset pediatric BD has been associated with higher rates of psychotic symptoms. This frequency of psychotic symptoms...
may increase the risk of low response to treatment in the long term in individuals with early onset of BD (7–10). Psychotic symptoms in pediatric BD have been reported to have a negative impact on interepisodic functionality and improvement (11). In addition, the presence of psychotic symptoms was associated with an increased number of mood episodes, psychiatric hospitalizations, and psychiatric comorbidities (12).

Patients with BD show increased impulsivity not only in the manic state but also in the euthymic state (13). Impulsivity-related cognitive disorders in BD may reduce the ability of patients to cope with distressing and stressful life events. A low degree of coping with stress can be considered a situation that affects resilience. On the other hand, low levels of resilience may predispose patients with BD to behave impulsively in response to stress. Therefore, resilience may be closely related to BD, and the number of studies investigating this relationship is quite low (14).

The aim of our study was to evaluate the clinical phenomenology, comorbidity, and course in children and adolescents with BD. The findings of this study may be a guide for clinicians to evaluate the effect of admission symptoms on the clinical course of children and adolescents with BD. We evaluated clinical phenomenology of pediatric BD and prognostic factors such as resilience in children and adolescents in remission, and comorbidity was evaluated by a semistructured interview. We also aimed to evaluate resilience by comparing the group with and without psychotic symptoms.

Our hypothesis is that in children and adolescents, the onset of BD is with psychotic symptoms, differs from adults, and the clinical course may be adversely affected if accompanied by psychotic symptoms. Therefore, we evaluated the relationship between recurrent episodes, length of hospitalization, clinical improvement, comorbidity, resilience (we consider prognostic), and manic and psychotic symptoms (e.g., poor judgment, hallucination, and delusion). Our second hypothesis is that resilience has a positive effect on the clinical course in BD.

METHOD

Sample
The study group included 60 cases between 12 and 18 years of age who were admitted to the inpatient unit with BD between January 2015 and May 2018. Of these, 32 were girls and 28 were boys. These patients were hospitalized for being in manic episodes. Among those hospitalized with the diagnosis of BD, those in remission after discharge were included in the study. We determined the remission through Young Mania Rating Scale (YMRS). The inclusion criteria for this study were those hospitalized with a diagnosis of BD between the ages of 12 and 18 years and in remission in the post-discharge evaluation. Written informed consent was obtained from the patients included in the study and their parents. The exclusion criteria for this study were mental retardation in the family or child and BD induced by substance use.

Procedure
Patients in the emergency outpatient clinic were evaluated first, and those with indications for hospitalization (i.e., harm oneself and suicide attempt) were admitted to the inpatient unit. YMRS and Positive and Negative Syndrome Scale (PANSS) were administered during admission, at discharge, and during the remission period. Clinical Global Impression Scale (CGI) was applied at discharge. We also applied the Suicide Behavior Questionnaire (SBQ), Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS), Child and Youth Resilience Measure (CYRM) to the patients in the remission period. As we included the cases who did not trigger an episode by substance use and did not have mental retardation in our study, we excluded no patients. The diagnosis was made by the treatment team in the inpatient clinic using clinical observation and the YMRS and PANSS scales. As we included patients who had manic episodes during hospitalization, there were no patients with depressive episodes during the same hospitalization period. The patients were divided into two groups using PANSS according to whether they had psychotic symptoms or not.

Measures

Sociodemographic Data Form
The form was developed by the researchers, to evaluate the sociodemographic characteristics of the patients and when symptoms of BD were started, the family history of psychiatric disorder.

Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children Present and Lifetime Version
It is a semistructured interview form developed by Kaufman et al. (15) to determine the psychopathology of children and adolescents in the
past and present according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria. The reliability and validity study of the Turkish translation was conducted by Gokler and Unal in 2004 (16). K-SADS was used to detect comorbidity. In the last part of the scale, the general functionality of the child is determined (Children Global Assessment Scale).

Clinical Global Impression Scale
The scale was developed by Guy et al. (17) in 1976 to evaluate the progress of all psychiatric disorders at any age for clinical research purposes. CGI-S is used to indicate the severity of the disorder. CGI-I is used to evaluate global recovery. The extent to which the person with a psychiatric disorder changes according to the situation when he/she enters the study is evaluated between 1 and 7 points.

Young Mania Rating Scale
YMRS was completed by the interviewer to measure the intensity and change of the manic state and developed by Young and colleagues. In this scale, there are subgroups such as elevated mood, increased energy, sexual interest, sleep, irritability, speed and amount of speech, thought disorder, thought content, disruptive behavior, external appearance, and insight. The reliability and validity study of the Turkish translation was conducted by Karadag et al. (18).

Positive and Negative Syndrome Scale
It was developed by Kay et al. (19) in 1987 and is a semistructured interview scale with a 30-item and 7-point severity assessment. The PANSS is scored by summation of rating across items such that the potential ranges are 7–49 for the Positive and Negative Scales and 16–112 for the General Psychopathology Scale. The reliability and validity study of the Turkish translation was conducted by Kostakoglu et al. (20). The PANSS was used to determine psychotic symptoms.

The Child and Youth Resilience Measure
The CYRM is a measurement tool that allows the collection of information about the psychological resilience of children and adolescents. The short-form study of the scale was conducted by Liebenberg, Ungar, and LeBlanc (21) in 2013, and a 12-item structure was obtained from two different studies. Items are rated on a 5-point scale from 1 (does not describe me at all) to 5 (describes me a lot). Higher scores indicate higher levels of resilience. Turkish validity and reliability study of the short version was conducted by Arslan in 2015 (22).

The Suicide Behavior Questionnaire
This inventory was developed by Linehan et al. (23) in 1981, and Turkish validity and reliability study of the SBQ was conducted by Bayam (24). The lowest score that can be obtained from the suicidal behavior questionnaire is 0 and the highest score is 14. The degree of suicidal behavior severity increases when the score increases.

Statistical Analysis
Statistical analysis was performed with IBM SPSS version 21.0 (IBM Corp., Released 2012, Armonk, NY, USA) package program. Descriptive statistics were given as mean, standard deviation, median, minimum, maximum, frequency, and percentage. Pearson’s Chi-squared and Fisher’s exact test were used to compare discrete variables. The Shapiro–Wilk test was used to determine the consistency of continuous variables to normal distribution. Intergroup comparisons of continuous variables were performed with the independent (Student’s) t-test and the Mann–Whitney U test. Logistic regression analysis was used to determine the independent variables predicting some clinical features (recurrent episodes, duration of hospitalization, CGI-S, resilience, and comorbidities) of the patients. A value of p<0.05 was accepted as statistically significant.

RESULTS
Our study was carried out with 60 patients. The study sample was divided into two groups as psychotic symptoms accompanied and not. There were 46 (76.7%) patients with psychotic symptoms and 14 patients (23.3%) without psychotic symptoms. There was a statistically significant difference between the groups in terms of gender distribution (p=0.031) (Table 1).

When the symptoms of the participants were examined, the most common symptom was found to be a decreased need for sleep (90%). A statistically significant difference was found for suspiciousness in terms of initial symptoms (p<0.001, Table 2). The elevated mood was found to be statistically higher in the group without psychotic symptoms.

The diagnosis of discharge was the main diagnosis received by the patients during follow-up, and the diagnosis of hospitalization was evaluated as the preliminary diagnosis. The diagnosis was made in the inpatient clinic accompanied by the treatment team’s YMRS and PANSS scales. The preliminary diagnosis
was made by the psychiatrist who evaluated it in the emergency clinic with a clinical interview. The preliminary diagnoses of the patients included in the study were 61.7% (n=37) of psychotic mania, 23.3% (n=14) of BD without psychotic features, and 15% (n=9) of psychotic disorder. The discharge diagnoses were 83.3% (n=50) of psychotic mania and 16.7% (n=10) of BD without psychotic features. These patients, referred to as "psychotic disorder," were evaluated with a preliminary diagnosis of psychotic disorder at the time of hospitalization and were diagnosed with mania during hospitalization. They were not diagnosed with a psychotic disorder. When 80% of the cases showed continuity of diagnosis, 20% of the diagnosis was found to change. There was a statistically significant difference between the groups with and without psychotic symptoms in terms of preliminary and discharge diagnosis variables (p<0.001, Table 2). The group without psychotic features was initially diagnosed with BD without psychotic features, but the patients who were admitted to the hospital with the preliminary diagnosis of psychotic disorder were diagnosed with psychotic mania at discharge.

CGI scores, Children Global Assessment Scale (CGAS) scores, CYRM, and SBQ scores are shown in Table 3, and no statistically significant difference was found. YMRS scores were significantly higher in the group with psychotic symptoms at the time of admission. The related data are shown in Table 3.

When the PANSS scores at admission were compared between the two groups, positive subscale scores (p<0.001), general psychopathology subscale scores (p=0.031), and total scores (p<0.001) were statistically significantly higher in the psychotic group. When the PANSS scores in the remission state were compared, the general psychopathology subscale score was significantly higher in the group without psychotic symptoms (p=0.019). The related data are shown in Table 3.

The data on comorbidity are shown in Table 4. While there was no significant difference between the two groups in terms of comorbidities other than ADHD, ADHD was statistically significantly higher in the group without psychotic symptoms (p=0.023).

Recurrent episodes, duration of hospitalization, getting into remission with clozapine, CGI severity, CGI improvement, CGAS, CYRM, and comorbidities were evaluated in univariate logistic regression analysis in predicting poor judgment (Table 5). In the multivariate logistic regression model, CGI disease severity and CGI improvement were statistically significant in predicting poor judgment. CGI severity increases by 6.16 times

---

**Table 1: Sociodemographic characteristics**

|                      | With psychotic symptoms (n=46) | Without psychotic symptoms (n=14) | X² | P   |
|----------------------|--------------------------------|----------------------------------|----|-----|
| **Min–Max**          | Mean±SD                        | Mean±SD                          |    |     |
| Age a                | 14–21                          | 17.87±1.46                       | 17.65±1.38 | 18.57±1.55 | 0.061 |
| Age at diagnosis a   | 11–17                          | 15.63±1.40                       | 15.59±1.39 | 15.79±1.47 | 0.0646|
| Gender b             |                                 | 4.673                            | 0.031*|
| Female               | 21 (45.7)                      | 11 (78.6)                        |
| Male                 | 25 (54.3)                      | 3 (21.4)                         |
| Educational status b |                                 | 3.901                            | 0.142|
| School left          | 19 (41.3)                      | 10 (71.4)                        |
| Continued            | 20 (43.5)                      | 3 (21.4)                         |
| Correspondence       | 7 (15.2)                       | 1 (7.1)                          |
| Working status c     |                                 | 1.000                            |     |
| Working              | 8 (17.4)                       | 2 (14.3)                         |
| Not working          | 38 (82.6)                      | 12 (85.7)                        |
| SES c                |                                 | 0.756                            |     |
| Lower than 2000 tl   | 16 (34.8)                      | 4 (28.6)                         |
| 2000 tl and above    | 30 (65.2)                      | 10 (71.4)                        |

Min: Minimum; Max: Maximum; SD: Standard deviation; SES: Socioeconomic status; *: P<0.05; a: Student’s t-test; b: Pearson’s Chi-squared test; c: Fisher’s exact test.
### Table 2: Clinical variables

|                        | With psychotic symptoms (n=46) | Without psychotic symptoms (n=14) | $\chi^2$ | P  |
|------------------------|-------------------------------|-----------------------------------|----------|----|
| **Recurrent episode**  |                               |                                   |          |    |
| With                   | 11 (23.9)                     | 5 (35.7)                          | 0.492    |    |
| Without                | 35 (76.1)                     | 9 (64.3)                          |          |    |
| **Hospitalization length** | 4–200 (40.11±37.33)      | 4–45 (23.00±11.95)               | -1.478   | 0.139 |
| **Time to remission**  | 5–186 (37.15±35.28)          | 6–38 (18.64±10.63)               | -1.879   | 0.06 |
| **Decreased need for sleep** |                             |                                   | 0.617    |    |
| Yes                    | 54 90                         | 42 (91.3)                         |          |    |
| No                     | 6 10                          | 4 (8.7)                           |          |    |
| **Increased speech**   |                               |                                   | 0.128    |    |
| Yes                    | 48 80                         | 39 (84.8)                         |          |    |
| No                     | 12 20                         | 7 (15.2)                          |          |    |
| **Irritability**       |                               |                                   | 0.155    |    |
| Yes                    | 45 75                         | 32 (69.6)                         |          |    |
| No                     | 15 25                         | 14 (30.4)                         |          |    |
| **Motor hyperactivity**|                               |                                   | 0.086    |    |
| Yes                    | 44 73.3                       | 31 (67.4)                         |          |    |
| No                     | 16 26.7                       | 15 (32.6)                         |          |    |
| **Elevated mood**      |                               |                                   | 0.006*   |    |
| Yes                    | 43 71.7                       | 29 (63)                           |          |    |
| No                     | 17 28.3                       | 17 (37)                           |          |    |
| **Grandiosity**        |                               |                                   | 0.195    |    |
| Yes                    | 40 66.7                       | 33 (71.7)                         |          |    |
| No                     | 20 33.3                       | 13 (28.3)                         |          |    |
| **Suspiciousness**     |                               |                                   | <0.001*  |    |
| Yes                    | 39 65                         | 36 (78.3)                         |          |    |
| No                     | 21 35                         | 10 (21.4)                         |          |    |
| **Increased goal-directed activity** |                     |                                   | 0.034    | 0.854 |
| Yes                    | 33 55                         | 25 (54.3)                         |          |    |
| No                     | 27 45                         | 21 (45.7)                         |          |    |
| **Hypersexuality**     |                               |                                   | 0.193    |    |
| Yes                    | 9 15                          | 5 (10.9)                          |          |    |
| No                     | 51 85                         | 41 (89.1)                         |          |    |
| Preliminary diagnosis  |                               |                                   | 60.00    | <0.001* |
| Psychotic mania        |                               |                                   |          |    |
| BD manic episode       | 37 (80.4)                     | 0 (0)                             |          |    |
| Psychotic disorder     | 0 (0)                         | 14 (100)                          |          |    |
| Discharge diagnosis    |                               |                                   | <0.001*  |    |
| Psychotic mania        | 46 (100)                      | 4 (28.6)                          |          |    |
| BD manic episode       | 0 (0)                         | 10 (71.4)                         |          |    |

Min: Minimum; Max: Maximum; SD: Standard deviation; BD: Bipolar disorder; a: Fisher’s exact test; b: Mann–Whitney U test; c: Pearson’s Chi-squared test; *: P<0.05.
with every 1 point increase compared with the absence of poor judgment \(\text{OR}=6.16, 95\% \text{ confidence interval}=(1.55–24.55), p=0.010\). The probability of poor judgment increased by 2.96 times as CGI improvement increased by 1 point each \(\text{OR}=2.96, 95\% \text{ confidence interval}=(1.17–7.50), p=0.022\).

In the multivariate logistic regression model, only recurrent episodes were statistically significant in predicting auditory hallucinations. The auditory hallucination group was less likely to have recurrent episodes \(\text{OR}=0.23, 95\% \text{ confidence interval}=(0.06–0.86), p=0.029\).

Except for CGI severity, the p-value was greater than 0.25 for all other variables in predicting persecutory delusions. Although the CGI severity score increased by 3.25 times in each unit increase, this was not statistically significant \(\text{OR}=3.25, 95\% \text{ confidence interval}=(0.89–11.90), p=0.075\).

**DISCUSSION**

In this study, psychotic symptoms were observed in 76.7% of the cases, but we expected more frequent psychotic symptoms in children and adolescents with BD. This finding is consistent with the literature reporting that the rate of psychotic symptoms in BD in children and adolescents was 40% (25,26) and that it ranged from 16% to 60% (26–28). In a study investigating the relationship between the phenomenology of BD and the age at which the disease began, the fact that psychotic features were higher in adolescent-onset cases than in adult-onset cases supports our study (29). Finally, this finding supports our hypothesis that the onset of BD in children and adolescents progresses with psychotic symptoms, unlike adults.
In our study, the male gender was found to be significantly higher in the psychotic group. Similarly, psychotic features are twice as high in male adolescent bipolar inpatients (30). In contrast, no gender differences were reported in terms of psychotic features (31).

When we evaluated the manic symptoms, decreased need for sleep was the most common.
These data are consistent with the study reporting that decreased need for sleep is the second most common symptom (39%) (25). In addition, another study reported that decreased need for sleep is a common symptom in both adolescent and adult age groups (32). In our study, increased speech was the second most common symptom and was consistent with the literature (25). While the rate of irritability was the third most common symptom with 67%, it was found to be consistent with studies indicating that irritability is a common symptom in pediatric BD (33,34), but not with studies reporting that irritability is the most common symptom in children and adolescents (35–38). Considering the studies reporting that irritability is seen more frequently in younger ages, the higher age group in our sample may explain that irritability is the third most common symptom. Our findings are also consistent with a meta-analysis (26), which evaluates the grandiosity rate as 78% and states that hypersexuality is the least sensitive symptom.

Although elevated mood and grandiosity were reported as cardinal symptoms (39), elevated mood was found to be significantly higher in the group without psychotic features in our study. This finding supports our hypothesis that psychotic mania is severe.

Suspiciousness was significantly higher in the psychotic symptoms group. This finding was consistent with the study that reported suspiciousness was significantly higher in adult bipolar patients with psychotic symptoms (40), and the study reported a high rate of paranoid ideas in mania cases beginning in 15–20 years (41). In a study investigating the prodrome period in adolescents, suspiciousness was found to be significantly higher in the prodromal process in psychotic mania (42). The high suspiciousness rate among the first symptoms in our study may be due to the difficulty of separating this period from the prodromal process.

It was found in the literature that the CGI disease severity scale and CGAS score were not affected in the presence of psychotic symptoms, which was compatible with our study (40,43). In a study comparing CGAS scores in children and adolescents with bipolar 1 and 2 disorders (44), the fact that it was lower in bipolar 1 disorder could be considered consistent with the low CGAS score in our study. CGAS score in this study was not compatible with the studies in the literature (45–49). The reason for this was the evaluation of the CGAS score in the remission period in our study.

There is no study on resilience in adolescents with BD. There is also a limited number of studies on adult BD. When we examine studies investigating resilience in adult bipolar cases, it is seen that bipolar cases show statistically significantly lower resilience levels compared with healthy controls (14,50–53). In an adult study comparing schizophrenia and bipolar

| Variable                        | Uncorrected OR | 95% CI       | p   | Corrected OR | 95% CI       | p   |
|---------------------------------|----------------|--------------|-----|--------------|--------------|-----|
| Recurrent episode               |                |              |     |              |              |     |
| Yes                             | 1.50           | 0.47–4.84    | 0.494 |              |              |     |
| No                              | Reference      |              |     |              |              |     |
| Length of hospitalization       | 1.01           | 0.99–1.03    | 0.109 |              |              |     |
| Remission with clozapine        |                |              |     |              |              |     |
| Yes                             | 4.00           | 0.67–23.94   | 0.129 |              |              |     |
| No                              | Reference      |              |     |              |              |     |
| CGI severity                    | 7.08           | 1.87–26.87   | 0.004* | 6.16         | 1.55–24.55   | 0.010* |
| CGI improvement                 | 3.17           | 1.33–7.54    | 0.009* | 2.96         | 1.17–7.50    | 0.022* |
| CGAS                            | 0.96           | 0.92–1.01    | 0.126 |              |              |     |
| CYRM                            | 0.95           | 0.88–1.03    | 0.191 |              |              |     |
| Number of comorbidities         | 1.11           | 0.78–1.56    | 0.565 |              |              |     |
| Comorbidity                     |                |              |     |              |              |     |
| Yes                             | 2.26           | 0.43–11.98   | 0.339 |              |              |     |
| No                              | Reference      |              |     |              |              |     |

CI: Confidence interval; OR: Odds ratio; CGI: Clinical Global Impression; CGAS: Children Global Assessment Scale; CYRM: Child and Youth Resilience Measure; *: P<0.05.
subjects with healthy controls, the lowest resilience level was observed in the schizophrenia group (54). In our study, as both groups consisted of severe cases requiring hospitalization, resilience levels may not differ. Further studies are needed to predict the effect of resilience on treatment response.

The hospitalization YMRS score was found to be significantly higher in the psychotic group. This finding is consistent with the data of a study indicating that the YMRS score was significantly higher in adult bipolar patients when accompanied by psychotic symptoms (40). Furthermore, the fact that YMRS scores correlate significantly with disease severity supports our hypothesis (55).

An adult study indicating that PANSS total score and positive subscale score were significantly higher in the psychotic group supports our study (40). In our study, PANSS general psychopathology subscale score was found to be higher in patients without psychotic symptoms at remission status. This finding may be due to the fact that the general psychopathology subscale was not evaluating psychotic symptoms. The fact that there was no difference between the two groups in terms of negative subscale scores in our study may be considered consistent with the study (56), which states that the negative symptoms seen in BD do not last for more than 18 months and their prognostic significance is limited.

While there were 51 (85%) cases with at least one comorbid diagnosis, no statistically significant difference was found between with and without psychotic symptoms. A study shows 76.2% of cases with at least one comorbid diagnosis supports our study (57). Depression as the most common comorbidity in our study is consistent with the data of the study, which states that depression is one of the most common signs of pediatric BD and is often the first symptom (58). In a follow-up study with children with major depressive disorder, 31.7% of the patients reported bipolarity (59). Depressive patients with a family history of BD and no history of mania may be in the prodromal period of BD (60). In our study, no significant difference was found in the groups with and without psychotic symptoms in terms of comorbid depression. This finding is consistent with a study that reported no difference in the group with and without psychotic symptoms in the adult study (61). A study conducted with adolescents investigating the prodrome period of BD supports our study by reporting that there is no difference in the group with and without psychotic symptoms in terms of depression (42).

When we examine the literature, ADHD is a common comorbid diagnosis (5,26,45,57,62–66). The fact that ADHD comorbidity was found to be higher in bipolar patients and stating that patients with ADHD comorbidity had a tendency to exhibit irritable mood rather than elevated mood was consistent with our study (66). Further studies of the high rate of comorbidities between ADHD and bipolarity show that both disorders exhibit the same neurocognitive disorders of executive functions, verbal memory, social cognition, and processing rate.

The probability of poor judgment increases by 6.16 times the CGI disease severity with each score. In the case of poor judgment, we expect the disease to be more severe. The probability of poor judgment increases 2.96 times as the CGI improvement increases with each score. It is a finding that we expect a worse degree of improvement if the judgment is poor. Knowing that poor judgment is seen at a higher rate in the young age group (26) suggests that poor judgment is poor prognostic in this regard, such as early onset age. In an adult study, poor judgment was found to be statistically significant in psychotic patients (40). We found a statistically insignificant correlation with CGI severity in predicting persecutory delusion. For every 1 point in CGI severity, the probability of persecutory delusion increased by 3.25 times. It has been reported that mood-incongruent psychotic features are associated with higher relapse in adults with a history of manic episodes with psychotic features (67). As persecutory delusion is considered mood-incongruent (68), it can be thought that persecutory delusion is a predictor of more serious disease and poor prognosis.

Our study has many limitations. Considering the prevalence of BD in children and adolescents and some of them receiving outpatient treatment, the small sample size is one of our limitations. The number of patients with psychotic symptoms in our study was higher than nonpsychotic bipolar children and adolescents in our study. It was thought that this situation prevented us from finding statistically significant results in the analyses that required a comparison between the two groups. The cases included in our study were children and adolescents diagnosed as bipolar 1 disorder because they showed signs of mania. Therefore, data on bipolar spectrum disorder could not be obtained. As the K-SADS was a semistructured interview form that we used in our study, it was not possible to obtain information about the frequency of these disorders in comorbidities because it did not screen some psychiatric disorders
(somatoform disorder, sexual identity disorder, dissociative disorder, and specific learning disorder) that may be seen in children and adolescents. The Turkish version of BD diagnosis according to the DSM-V classification system could not be used in this study because its validity and reliability were not completed in Turkish. Therefore, some new DSM-V diagnoses (such as DMDD) could not be evaluated. As a result, the increase of goal-directed activity criterion A in DSM-V could not be achieved in all cases.

CONCLUSION

No significant difference was found in both groups in terms of resilience. Poor judgment from manic symptoms and persecutory delusions from psychotic symptoms are findings that should be evaluated because they predict the clinical course. Evaluation of relevant predictors in larger study samples will give more significant results in predicting clinical course in patients with BD.

| Contribution Categories | Author Initials |
|------------------------|----------------|
| Category 1             | Concept/Design |
|                        | G.K., S.A.     |
|                        | Data acquisition | S.A., N.U. |
|                        | Data analysis/Interpretation | G.K., S.A. |
| Category 2             | Drafting manuscript | G.K., C.M. |
|                        | Critical revision of manuscript | S.A. |
| Category 3             | Final approval and accountability | S.A. |

Ethical Approval: The Bakirkoy Prof. Mazhar Osman Training and Research Hospital Ethics Committee granted approval for this study (date: 06.03.2018, number: 139).

Informed Consent: Informed consent was obtained from all participants.

Peer-review: Externally peer-reviewed.

Conflict of Interest: The authors declare that they have no conflict of interest.

Financial Disclosure: The authors declare that they have no financial support.

REFERENCES

1. Merikangas KR, Jin R, He JP, Kessler RC, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011; 68:241-251. [CrossRef]

2. Egeland JA, Hostetter AM, Pauls DL, Sussex JN. Prodromal symptoms before onset of manic-depressive disorder suggested by first hospital admission histories. J Am Acad Child Adolesc Psychiatry 2000; 39:1245-1252. [CrossRef]

3. Goldstein BI, Birmaher B. Prevalence, clinical presentation and differential diagnosis of pediatric bipolar disorder. Isr J Psychiatry Relat Sci 2012; 49:3-14.

4. Pavuluri MN, Birmaher B, Naylor MW. Pediatric bipolar disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 2005; 44:846-871. [CrossRef]

5. Geller B, Tillman R, Bolhofer K, Zimmerman B. Child bipolar 1 disorder: prospective continuity with adult bipolar 1 disorder: characteristics of second and third episodes; predictors of 8-year outcome. Arch Gen Psychiatry 2008; 65:1125-1133. [CrossRef]

6. Gore FM, Bloem PJ, Patton GC, Ferguson J, Joseph V, Coffey C, et al. Global burden of disease in young people aged 10-24 years: a systematic analysis. Lancet 2011; 377:2093-2102. [CrossRef]

7. Carlson GA, Bromet EJ, Sievers S. Phenomenology and outcome of subjects with early- and adult-onset psychotic mania. Am J Psychiatry 2000; 157:213-219. [CrossRef]

8. Joyce PR. Age of onset in bipolar affective disorder and misdiagnosis as schizophrenia. Psychol Med 1984; 14:145-149.

9. McGlashan TH. Adolescent versus adult onset of mania. Am J Psychiatry 1988; 145:221-223. [CrossRef]

10. Rosen LN, Rosenthal NE, Van Dusen PH, Dunner DL, Fieve RR. Age at onset and number of psychotic symptoms in bipolar I and schizoaffective disorder. Am J Psychiatry 1983; 140:1523-1524.

11. Cannon M, Jones P, Gilvary C, Rifkin L, McKenzie K, Foerster A, et al. Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences. Am J Psychiatry 1997; 154:1544-1550.

12. Hua LL, Wilens TE, Martelon M, Wong P, Wozniak J, Biederman J. Psychosocial functioning, familiality, and psychiatric comorbidity in bipolar youth with and without psychotic features. J Clin Psychiatry 2011; 72:397-405. [CrossRef]

13. Strakowski SM, Fleck DE, DelBello MP, Adler CM, Shear PK, Kotwal R, et al. Impulsivity across the course of bipolar disorder. Bipolar Disord 2010; 12:285-297. [CrossRef]

14. Choi JW, Cha B, Jang J, Park CS, Kim BJ, Lee CS, et al. Resilience and impulsivity in euthymic patients with bipolar disorder. J Affect Disord 2015; 170:172-177. [CrossRef]

15. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36:980-988. [CrossRef]

16. Gokler B, Unal MF, Ozsungur B, Cengel Kultur SE, Akdemir D, Mengü YI. The validity and reliability of the Turkish adaptation of the schedule for affective disorders and schizophrenia for school-aged children- present and lifetime version (K-SADS-PL): initial reliability and validity data. Turk J Psychiatry 2004; 11:109-116. [Turkish]

17. Guy W. ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW publication no. ADM 76–338). Rockville: U.S. National Institute of Mental Health, 1976.

18. Karadag F, Oral ET, Aran Yalcin F, Erten E. Reliability and validity of Turkish translation of young mania rating scale. Türk Psikiyatr Derg 2001; 13:107-114. [Turkish]
19. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276. [CrossRef]

20. Kostakoglou A, Batur S, Tiryaki A, Gogus A. The validity and reliability of the Turkish version of the positive and negative syndrome scale (PANSS). Turkish Journal of Psychology 1999; 14: 23-32. (Turkish)

21. Liebenberg L, Ungar M, LeBlanc JC. The CYRM-12: A brief measure of resilience. Can J Public Health 2013; 104:131-135.

22. Arslan G. Psychometric properties of child and youth resilience measure (CYRM-12): The study of reliability and validity. Ege Egitim Derg 2015; 1:1-12. [Turkish]

23. Linehan MM, Nielsen SL. Assessment of suicide ideation and parasuicide: hopelessness and social desirability. J Consult Clin Psychol 1981; 49:773-775. [CrossRef]

24. Bayam G, Dilbaz N, Bitlis V, Holat H, Tuzer T. The association between suicidal behavior and depression, hopelessness, and suicidal ideation: The validity and reliability study of the suicidal behavior scale. The Journal of Crisis 1995; 3:223-225. (Turkish)

25. Limsuwan N. Clinical presentations of bipolar disorder in children and adolescents. J Med Assoc Thai 2014; 97:179-183.

26. Kowatch RA, Youngstrom EA, Danielyan A, Findling RL. Review and meta-analysis of the phenomenology and clinical characteristics of mania in children and adolescents. Bipolar Disord 2005; 7:483-496. [CrossRef]

27. Wozniak J, Biederman J, Kiely K, Ablon JS, Faraone SV, Mundy E, et al. Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children. J Am Acad Child Adolesc Psychiatry 1995; 34:867-876. [CrossRef]

28. Geller B, Williams M, Zimmerman B, Frazier J, Beringer L, Warner KL. Prepubertal and early adolescent bipolarity differentiation from ADHD by manic symptoms, grandiose delusions, ultra-rapid or ultradian cycling. J Affect Disord 1998; 51:81-91. [CrossRef]

29. Erkiran M, Karamustafalioğlu N, Tomruk N, Kahraman E, Alpay N. Phenomenological differences between adolescent and adult onset mania: a comparative study. Turk Psikiyatri Derg 2003; 14:21-30. [Turkish]

30. Landolt AB. Follow-up studies on circular manic-depressive reactions occurring in the young. Bull N Y Acad Med 1957; 33:65-73.

31. Faedda GL, Baldessarini RJ, Glovinsky IP, Austin NB. Pediatric bipolar disorder: phenomenology and course of illness. Bipolar Disord 2004; 6:305-313. [CrossRef]

32. Ryles F, Meyer TD, Adan-Manes J, MacMillan I, Scott J. A systematic review of the frequency and severity of manic symptoms reported in studies that compare phenomenology across children, adolescents and adults with bipolar disorders. Int J Bipolar Disord 2017; 5:4. [CrossRef]

33. Van Meter AR, Burke C, Kowatch RA, Findling RL, Youngstrom EA. Ten-year updated meta-analysis of the clinical characteristics of pediatric mania and hypomania. Bipolar Disord 2016; 18:19-32.

34. Pavuluri MN, Herbener ES, Sweeney JA. Psychotic symptoms in pediatric bipolar disorder. J Affect Disord 2004; 80:19-28. [CrossRef]

35. Lázaro L, Castro-Fornieles J, de la Fuente JE, Baeza I, Morer A, Pàmias M. Differences between prepubertal- versus adolescent-onset bipolar disorder in a Spanish clinical sample. Eur Child Adolesc Psychiatry 2007; 16:510-516. [CrossRef]

36. Song M, Yoon H, Choi I, Hong SD, Joung YS. Differences of clinical characteristics and phenotypes between prepubertal-and adolescent-onset bipolar disorders. J Korean Med Sci 2010; 25:912-917. [CrossRef]

37. Jerrell JM, Shugart MA. A comparison of the phenomenology and treatment of youths and adults with bipolar I disorder in a state mental health system. J Affect Disord 2004; 80:29-35. [CrossRef]

38. Safer DJ, Magno Zito J, Safer AM. Age-grouped differences in bipolar mania. Compr Psychiatry 2012; 53:1110-1117. [CrossRef]

39. Craney JL, Geller B. A prepubertal and early adolescent bipolar disorder-I phenotype: review of phenomenology and longitudinal course. Bipolar Disord 2003; 5:243-256. [CrossRef]

40. Canuso CM, Bossie CA, Zhu Y, Youssef E, Dunner DL. Psychotic symptoms in patients with bipolar mania. J Affect Disord 2008; 111:164-169. [CrossRef]

41. Carlson GA, Goodwin FK. The stages of mania. A longitudinal analysis of the manic episode. Arch Gen Psychiatry 1973; 28:221-228. [CrossRef]

42. Correll CU, Penzner JB, Frederickson AM, Richter JJ, Auther AM, Smith CW, et al. Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome. Schizophr Bull 2007; 33:703-714. [CrossRef]

43. Demeter CA, Youngstrom EA, Carlson GA, Frazier TW, Rowles BM, Lingler J, et al. Age differences in the phenomenology of pediatric bipolar disorder. J Affect Disord 2013; 147:295-303.

44. Axelson D, Birmaher B, Strober M, Gill MK, Valeri S, Chiappetta L, et al. Phenomenology of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry 2006; 63:1139-1148.

45. Hafeman D, Axelson D, Demeter C, Findling RL, Fristad MA, Kowatch RA, et al. Phenomenology of bipolar disorder not otherwise specified in youth: a comparison of clinical characteristics across the spectrum of manic symptoms. Bipolar Disord 2013; 15:240-252. [CrossRef]

46. Findling RL, Robb A, McNamara NK, Pavuluri MN, Kafantaris V, Scheffer R, et al. Lithium in the acute treatment of bipolar I disorder: A double-blind, placebo-controlled study. Pediatrics 2015; 136:885-894. [CrossRef]

47. Birnbaum S, Hazell PL, Hanstock TL, Lewin TJ. Bipolar disorder subtypes in children and adolescents: demographic and clinical characteristics from an Australian sample. J Affect Disord 2015; 175:98-107. [CrossRef]

48. Tillman R, Geller B, Klages T, Corrigan M, Bolhofner K, Zimmerman B. Psychotic phenomena in 257 young children and adolescents with bipolar I disorder: Delusions and hallucinations (benign and pathological). Bipolar Disord 2008; 10:45-55. [CrossRef]

49. Peters AT, Weinstein SM, Isaia A, Van Meter A, Zulauf CA, West AE. Symptom dimensions and trajectories of functioning among bipolar youth: A cluster analysis. J Psychiatr Pract 2018; 24:146-157. [CrossRef]
50. Hofer A, Mizuno Y, Wartelsteiner F, Fleischhacker WW, Kemmler G, Mimura M, et al. Quality of life in schizophrenia and bipolar disorder: The impact of symptomatic remission and resilience. Eur Psychiatry 2017; 46:42-47. [CrossRef]

51. Mizuno Y, Hofer A, Suzuki T, Kemmler G, Saruta J, Wartelsteiner F, et al. Clinical and biological correlates of resilience in patients with schizophrenia and bipolar disorder: A cross-sectional study. Schizophr Res 2016; 175:148-153. [CrossRef]

52. Lee D, Cha B, Park CS, Kim BJ, Lee CS, Seo JY, et al. Effects of resilience on quality of life in patients with bipolar disorder. J Affect Disord 2017; 207:434-441. [CrossRef]

53. Bozikas VP, Parlapani E, Ntouros E, Bargiotas SI, Floros G, Nazlidou EI, et al. Resilience predicts social functioning in clinically stable patients with bipolar disorder. J Nerv Ment Dis 2018; 206:567-574. [CrossRef]

54. Deng M, Pan Y, Zhou L, Chen X, Liu C, Huang X, et al. Resilience and cognitive function in patients with schizophrenia and bipolar disorder, and healthy controls. Front Psychiatry 2018; 9:279.

55. Fristad MA, Weller EB, Weller RA. The Mania Rating Scale: can it be used in children? A preliminary report. J Am Acad Child Adolesc Psychiatry 1992; 31:252-257. [CrossRef]

56. Husted JA, Beiser M, Iacono WG. Negative symptoms in the course of first-episode affective psychosis. Psychiatry Res 1995; 56:145-154. [CrossRef]

57. Soutullo CA, Escamilla-Canales I, Wozniak J, Figueroa-Quintana A, Gamazo-Garrán P, Biederman J. Pediatric bipolar disorder in a Spanish sample: Features before and at the time of diagnosis. J Affect Disord 2009; 118:39-47. [CrossRef]

58. Lish JD, Dime-Meenan S, Price RA, Hirschfeld RM. The national depressive and manic-depressive association (DMDA) survey of bipolar members. J Affect Disord 1994; 31:281-294. [CrossRef]

59. Geller B, Fox LW, Clark KA. Rate and predictors of prepubertal bipolarity during follow-up of 6- to 12-year-old depressed children. J Am Acad Child Adolesc Psychiatry 1994; 33:461-468.

60. Chang K, Howe M, Gallelli K, Miklowitz D. Prevention of pediatric bipolar disorder: Integration of neurobiological and psychosocial processes. Ann N Y Acad Sci 2006; 1094:235-247.

61. Keck PE Jr, McElroy SL, Harens JR, Altshuler LL, Nolen WA, Frye MA, et al. Psychosis in bipolar disorder: phenomenology and impact on morbidity and course of illness. Compr Psychiatry 2003; 44:263-269. [CrossRef]

62. Geller B, Sun K, Zimerman B, Luby J, Frazier J, Williams M. Complex and rapid-cycling in bipolar children and adolescents: A preliminary study. J Affect Disord 1995; 34:259-268. [CrossRef]

63. Soutullo CA, DelBello MP, Ochsner JE, McElroy SL, Taylor SA, Strakowski SM, et al. Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment. J Affect Disord 2002; 70:323-327. [CrossRef]

64. State RC, Frye MA, Altshuler LL, Strober M, Hwang S, Mintz J, et al. Chart review of the impact of attention-deficit/hyperactivity disorder comorbidity on response to lithium or divalproex sodium in adolescent mania. J Clin Psychiatry 2004; 65:1057-1063. [CrossRef]

65. West SA, Strakowski SM, Sax KW, Minnery KL, McElroy SL, Keck PE Jr. The comorbidity of attention-deficit hyperactivity disorder in adolescent mania: potential diagnostic and treatment implications. Psychopharmacol Bull 1995; 31:347-351.

66. Tohen M, Tsuang MT, Goodwin DC. Prediction of outcome in mania by mood-congruent or mood-incongruent psychotic features. Am J Psychiatry 1992; 149:1580-1584. [CrossRef]

67. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, (DSM IV). Fourth Ed. Virginia: American Psychiatric Association, 1994.